RICHMOND, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 4:30 pm (ET) on Tuesday, December 2, 2008 at the Piper Jaffray 20th Annual Health Care Conference in New York. The company will also update the financial community on its latest developments in its therapeutic programs and discuss other business matters at its annual Investor and Analyst Briefing to be held from 4:30 to 6:30 pm ET, on Wednesday, December 3, 2008.
The presentations will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentations will be archived on the Sangamo website for two weeks after the events.
Sangamo BioSciences, Inc. is focused on the research and development of
novel DNA-binding proteins for therapeutic gene regulation and modification.
The most advanced ZFP Therapeutic(TM) development program is currently in
Phase 2 clinical trials for evaluation of safety and clinical effect in
patients with diabetic neuropathy and ALS. Other therapeutic development
programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve
regeneration, Parkinson's disease and monogenic diseases. Sangamo's core
competencies enable the engineering of a class of DNA-binding proteins known
as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that
recognize a specific DNA sequence Sangamo has created ZFP transcription
factors (ZFP TF(TM)) that can control gene expression and, co
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved